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Abstract
Background: The introduction of HAART has initially improved the quality of life (QoL) of HIV-
positive (HIV+) patients, however body fat redistribution (BFR) and metabolic disorders associated
with long-term HAART use may attenuate this improvement. As access to treatment improves in
sub-Saharan Africa, the disfiguring nature of BFR (peripheral atrophy and/or central adiposity) may
deter treatment adherence and initiatives and decrease QoL. We examined the relationship
between BFR and domains of QoL in HAART-treated HIV+ African men and women with
(HIV+BFR, n = 50) and without (HIV+noBFR, n = 50) BFR in Rwanda.
Results: HIV+ subjects with BFR were less satisfied with their body image (4.3 ± 0.1 versus 1.5 ±
0.2; p < .001), self-esteem and social life (4.1 ± 1.4 versus 2.1 ± 0.3; p = 0.003). HIV+BFR were
more ashamed in public (4.5 ± 1.2 versus 1.1 ± 1.1), reported less confident about their health (4.6
± 1.4 versus 1.5 ± 1.2) and were frequently embarrassed due to body changes (4.1 ± 1.1 versus 1.1
± 0.9) (p < .001) than HIV+noBFR. HIV+ Rwandan women with BFR reported more dissatisfaction
with psychological (8.3 ± 2.9 versus 13.7 ± 1.9), social relationships (6.9 ± 2.3 versus 11.1 ± 4.1)
and HIV HAART-specific domain of wellbeing (3.1 ± 4.8 versus 6.3 ± 3.6) (p < .001). Age was
associated with independence (r2 = 0.691; p = 0.009) and marital status was associated with
psychological (r2 = 0.593; p = 0.019) and social relationships (r2 = 0.493; p = 0.007). CD4 count (r2
= 0.648; p = 0.003) and treatment duration (r2 = 0.453; p = 0.003) were associated with HIV
HAART-specific domain of wellbeing. HIV+ Rwandan women with BFR were significantly more
affected by abdominal adiposity (p < .001), facial and buttocks atrophy (p < .05) than HIV+ men
with BFR.
Conclusion: Body fat alterations negatively affect psychological and social domains of quality of
life. These symptoms may result in stigmatization and marginalization mainly in HAART-treated
African women, adversely affecting HAART adherence and treatment initiatives. Efforts to evaluate
self-perceived body fat changes may improve patients' wellbeing, HAART adherence and treatment
outcomes and contribute towards stability in quality of life continuum.
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Background
The psychological and social effects of Human Immuno-
deficiency Virus (HIV) and Acquired Immune Deficiency
Syndrome (AIDS) on patients' quality of life (QoL) have
been constantly fluctuating [1]. With the advent of highly
active antiretroviral therapy (HAART), people affected
with HIV/AIDS can now live a longer thriving life [2]. The
World Health Organization (WHO) '3 by 5', the Presiden-
tial Emergency Program for AIDS Relief (PEPFAR), bilat-
eral and multilateral agencies have facilitated resource-
limited countries including sub Saharan Africa to scale-up
HIV treatment, maintaining effective and appropriate
standard of care [3]. As a result of WHO guidelines and
global initiatives, HIV treatment efficacy in resource-lim-
ited countries is promising [4]. Although the benefits of
HIV treatment are well established [2], the use of HAART
in approximately 40–60% of patients, has been linked to
a constellation of treatment challenges, including meta-
bolic abnormalities and body fat redistribution (BFR),
often called HIV lipodystrophy [5,6].
The characteristics of BFR resulting in distinct abnormal
fat gain for the neck (buffalo hump), abdomen, breasts,
and/or fat loss for the face, limbs and buttocks are consid-
erably disfiguring [7]. BFR compromises HIV serostatus
privacy, producing social isolation and distress, resulting
in psychological repercussions [8]. In fact, HIV patients
with BFR would trade off length of life or accepted greater
risks of mortality in order to maintain a life free of body
fat alterations [9]. Therefore, BFR may influence patients'
beliefs about benefits of HAART, and decrease adherence
with subsequent adverse impact on patients' QoL [10].
Studies on QoL and BFR in HIV+ sub Saharan patients are
limited. Information regarding the relationship between
BFR and QoL is important as access to HAART for HIV+
patients in sub Saharan countries is steadily improving.
Therefore, we examined the relationship between BFR and
QoL in HAART-treated HIV+ African men and women
with BFR in Rwanda.
Methods
Subjects
Subjects with HIV infection on stable HAART were
enrolled in the study from August 2005 to July 2006. Sub-
jects attended routine medical follow-up and periodic
CD4 cell counts from tertiary health centres of Centre
Hospitalier Universitaire de Kigali, Treatment & Research
AIDS Centre and Centre Hospitalier Universitaire de
Butare. Subjects were also recruited from HIV/AIDS clinics
of Kimironko, Kicukiro, Bilyogo-Nyiranuma, Kinyinya
and Kacyiru Health Centres. Information regarding the
type and duration of HAART was obtained from subjects'
dispensation cards. Eligible subjects had documented HIV
infection, were 21–50 years and on stable WHO-recom-
mended HAART ≥ 6 months. Subjects had no active
opportunistic infections or significant symptoms of HIV
disease which could adversely influence their expectations
of quality of life and decrease performance status. Details
of the study procedures were given on volunteers' infor-
mation sheet. The benefits, confidentiality and voluntary
participation features of the study were explained and
written informed consent was obtained from all subjects.
Ethical approval was obtained through the National
Research Ethics Committee (Rwanda), and the University
of the Witwatersrand-Johannesburg (South Africa), an
institutional research partner to Kigali Health Institute.
Procedures
Trained research associates administered a validated ques-
tionnaire, in which subjects reported changes in fat con-
tent affecting the face, posterior neck, breasts, abdomen,
buttocks, upper and lower limbs [11]. The degree of body
fat redistribution was rated as absent  (score 0), mild
(noticeable on close inspection, score 1), moderate (read-
ily noticeable by the patient and the physician (score 2) or
severe (readily noticeable to a casual observer, (score 3).
The overall score was the mean of the scores given by the
patients and a score assigned to each patient by a consen-
sus of three clinicians working in the field of HIV/AIDS.
Presence and rating of BFR was confirmed in all subjects
by physical examination, in which 18% of HIV+ subjects
(from self-reports) were excluded from HIV+ patients with
moderate to severe BFR changes. For purposes of the cur-
rent study, a clinical diagnosis was given to HIV patients
with moderate (score 2) to severe (score 3) BFR, and an
overall mean score of ≥ 18 on a validated 7-item body fat
redistribution inventory for the face, neck, arms, breasts,
abdomen, buttocks and legs, with 21 as a highest score.
This was because self-perception of body changes in HIV
patients with mild (score 1) changes may not have consid-
erably influenced subjects' domains of quality of life. Sub-
jects were divided into those with moderate-to-severe BFR
(HIV+BFR, n = 50) and those with no BFR (HIV+noBFR, n
= 50). Subjects' demographic characteristics including
age, gender, occupation, education, data about HIV infec-
tion, type and duration of HAART and data on body fat
changes were all obtained at the time of administration of
the questionnaires.
Body composition and anthropometric measurements
were measured by an experienced investigator. For con-
sistency of data on skinfolds, one experienced investigator
located and measured all skinfolds. Height (m), weight
(Kg), body mass index (BMI) [calculated as weight (kg)/
height (m)2], waist and hip circumferences (cm), waist-to-
hip ratio (WHR) (calculated) were measured while the
subject was standing, wearing light clothing and no shoes.
Weight and height were measured to the nearest 0.1 kg
and 0.1 cm respectively. Waist and hip circumferences
were measured using an inelastic cloth tape. Waist circum-AIDS Research and Therapy 2007, 4:19 http://www.aidsrestherapy.com/content/4/1/19
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ference was measured at the narrowest circumference,
halfway between the lowest ribs and iliac crests. Hip cir-
cumference was measured at the level of the anterior supe-
rior iliac spine, where this could be palpated, otherwise at
the broadest circumference below the waist. Two meas-
urements were taken, and when there was a more than 2
cm difference between the two, a third measurement was
taken. The mean of the closest two measurements was
used to calculate WHR. Mid-triceps, mid-biceps, supra-
iliac and sub-scapular skinfolds were measured using
Lange™ Skinfold Callipers. Measurements were read to the
nearest 0.2 mm, and averaged for each skinfold site. The
sum of skinfold measures were used to predict percentage
body fat (% BFM) using derived equations and formulas
[12,13], applicable on a black population [14].
Outcome measures
Quality of life was measured using a summarized version
of the World Health Organization's Quality of Life HIV
instrument (WHOQOL-HIV) [15]. This is because
although HIV infection is now a chronic illness and qual-
ity of life is an important outcome measure, mainly in
HIV patients with body fat alterations, there are no vali-
dated instruments to assess the effects of body changes on
quality of life in HAART-treated HIV population [1]. The
instruments commonly used to assess QoL in HIV popu-
lation include the Medical Outcome Study SF-36 form
(MOS SF-36) widely used to assess QoL in general popu-
lation with chronic diseases [16], the HIV/AIDS-Targeted
Quality of Life instrument (HAT-QoL) [17] and the Multi-
dimensional Quality of Questionnaire for HIV/AIDS
(MQoL-HIV) [18]. However, most of these instruments
were developed before the HAART era, and were tested in
a single cultural setting usually in the developed world.
The WHOQOL-HIV instrument was developed for HIV
population and has been shown to be valid in multi-cul-
tural settings of heterogeneous social-economic strata
including African countries [14]. Quality of life was
assessed using the World Health Organization's Quality
of Life HIV short form instrument (WHOQOL HIV BREF).
The instrument contained items asking about how satis-
fied, how much, how completely, how bothered a person
feels about different aspects of their life in the previous
four weeks. The items were rated on a 5-point Likert inter-
val scale where 1 indicated low negative perceptions and
feelings, and 5 indicated very high positive perceptions
and feelings. For example an item on HIV disclosure
asked, "In the last four weeks, how much confident have
you been about people knowing that you are HIV posi-
tive?" The available responses were: 1 (not at all), 2 (a lit-
tle), 3 (a moderate amount), 4 (very much) and 5 (an
extreme amount). However, since the QoL of HIV patients
during the HAART era may fluctuate due to the positive
effects of HAART, counterbalanced by effects of body fat
changes [7], we included HIV HAART-specific domain of
five facets specific for HIV patients during the HAART era.
These items were generated from preliminary participants'
interviews, clinicians, social scientists working in the field
of HIV/AIDS and literature search [8,19]. These facets
included feeling ashamed in public, problems of dressing
style and size, feeling less confident about health, afraid of
HIV disclosure and being embarrassed due to the impact
of body fat alterations. Furthermore, to assess gender dif-
ferences in the impact of BFR on QOL, subjects with BFR
were asked to indicate how different body sites were
affected by the presence of body fat redistribution. Sub-
jects answered various questions such as 'in the past four
weeks, how are the changes on your face affected by feel-
ing ashamed in public places? Each item for different
body sites had responses ranging from 1 (not at all), 2 (a
little), 3 (a moderate amount), 4 (very much) and 5 (an
extreme amount). Other domains include overall rating
of quality of life, satisfaction with general health, and
looking forward with hope to a better future. Therefore,
the final instrument used in the current study was a short
form of the World Health Organisation HIV instrument
(WHOQOL HIV BREF), plus one domain of five facets to
form 28 items.
Statistical analysis
The data were analyzed using Fisher's Exact Test to deter-
mine the differences between groups, such as subject char-
acteristics and body fat changes associated with quality of
life. Continuous variables were analysed by paired t-tests.
Nonparametric responses to the QoL questionnaire were
analyzed using the Mann-Whitney Rank Sum Test
(Kruskal-Wallis statistic). Scores were calculated and sum-
marized so that facet scores were the mean of items in
each facet. Domain scores were obtained by adding the
facet mean scores in the respective domain, and dividing
the number of facets in that domain, and multiplying by
4, so that the score range were from 4 to 20. Lower scores
indicated poor self-perceived quality of life for the
assessed health measure. Mean domain scores for each of
the body parts affected were summarized by gender. Mul-
tiple linear regressions were performed to analyse the rela-
tionship between quality of life domain scores as
dependent variable and independent variables between
subject groups. All p values were 2-tailed, and statistical
significance was set at 0.05. All data analysis was per-
formed with STATA 8.1 statistical package (STATA Corp),
and presented as mean ± SD, number (%) or median
(interquartile range).
Results
The demographic, body composition and clinical charac-
teristics of the sample are presented in Table 1. Subject
groups did not differ considerably with regard to age, gen-
der, occupation, education and body mass index (BMI).AIDS Research and Therapy 2007, 4:19 http://www.aidsrestherapy.com/content/4/1/19
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HIV+BFR subjects received HAART for a significantly
longer duration, and had larger waist but smaller hip cir-
cumferences and larger WHR than HIV+noBFR subjects.
The sum skinfold and body fat mass did not differ
between groups as subjects four-site skinfold thicknesses
did not differ considerably (Table 1). Subjects were prima-
rily receiving World Health Organisation (WHO)-recom-
mended first line HAART regimens, with over 80%
received stavudine, lamivudine and nevirapine, a widely
used therapy in resource-limited regions of the world. The
use of HAART regimen did not significantly differ between
subject groups. CD4 cell counts for HIV+BFR men (333 ±
124) did not significantly differ from those of HIV+BFR
women (366 ± 130 cells/µl) (p = 0.631). Also the CD4 cell
counts for HIV+noBFR men (366 ± 133 cells/µl) were not
different from those of HIV+BFR women (287 ± 118 cells/
µl) (p = 0.413). HAART duration for HIV+BFR men was
not different from that of HIV+BFR women [69.5 (30.8)
versus 71.2 (26.9) months; p = 0.713]. Similarly HAART
duration for HIV+noBFR men and women did not differ
between groups [45.1 (13.3) versus 48.5 (15.5) months; p
= 0.697].
Quality of life scores by facets
HIV+BFR subjects were less satisfied with self-esteem and
satisfaction with social life (4.1 ± 1.4 versus 2.1 ± 0.3; p =
0.003), body image and appearance (4.3 ± 0.1 versus 1.5
± 0.2; p < .001), negative feelings about their job and rou-
tine house hold chores (4.5 ± 1.1 versus 3.1 ± 0.2; p =
0.027). HIV+BFR also reported more emotional stress
than their HIV+noBFR counterparts (4.3 ± 1.4 versus 2.3
± 0.7; p < .001). Subjects with body fat alterations further
reported less satisfaction with interpersonal relationships
(4.3 ± 1.2 versus 1.3 ± 1.2; p < .001), practical social sup-
port (4.3 ± 1.1 versus 1.1 ± 0.3; p < .001) and felt less
respected and accepted by others (4.7 ± 1.1 versus 2.1±
1.5; p < .001). The wellbeing associated with spirituality,
religion and beliefs (4.2 ± 1.2 versus 4.3 ± 1.0; p = 0.126)
and satisfaction with sexual life (4.5 ± 1.7 versus 4.5 ± 0.2;
p = 0.981) did not differ considerably between groups.
However, HIV+BFR subjects reported more significant
feeling ashamed in public places (4.5 ± 1.2 versus 1.1 ±
1.1), problems of dressing style and size (4.7 ± 1.6 versus
1.1 ± 0.7), less confident about their health (4.6 ± 1.4 ver-
sus 1.5 ± 1.2), fear of HIV disclosure (4.1 ± 1.8 versus 1.1
± 1.3) and humiliation due to the impact of body fat alter-
ations (4.1 ± 1.1 versus 1.1 ± 0.9) (p < .001).
Body changes and quality of life
Table 2 lists subjects' mean scores on various domains of
quality of life and effects of body fat alterations on QoL
between African men and women. HIV+BFR subjects
reported significantly less satisfaction with psychological
wellbeing and social relationships. There were no consid-
erable differences with regard to physical and independ-
ence domains of quality of life. Also, satisfaction with
overall quality of life between subjects groups did not dif-
fer considerably (Table 2). Women with BFR reported less
satisfaction with psychological wellbeing and social rela-
tionships. Women with BFR also reported more feeling
ashamed in public and having problems of dressing style
and size, fear of HIV disclosure and reported more embar-
rassment due to the impact of body changes (Table 2).
There were no gender differences in physical functioning,
independence wellbeing and overall rating of quality of
life between subject groups. Marital status was associated
with psychological (r2 = 0.59; p < 0.05) and social rela-
Table 1: Sample characteristics, disease and body composition 
profiles
HIV+noBFR HIV+BFR p
Age (years) 37.6 ± 6.3 37.5 ± 6.9 0.909
Number (females) 50 (60%) 50 (60%) -
Occupation
Public or private 
employment
6 (12%) 7 (14%) 0.685
Farming or livestock 29 (58%) 27 (54%) 0.896
Self-employed 9 (18%) 10 (20%) 0.985
Unemployed 6 (12%) 6 (12%) 1.000
Education
≤ Secondary (High) 
school
20 (40%) 21 (42%) 0.986
Secondary (High) 
school
30 (60%) 29 (58%) 0.983
Tertiary (College) 
education
1 (2%) - -
Marital status
Married 21 (42%) 9 (18%) 0.003
Separated 5 (10%) 6 (12%) 0.863
Widow or widower 18 (36%) 24 (48%) 0.060
Cohabiting 6 (12%) 11 (22%) 0.019
Smoking
Yes 10 (20%) 7 (14%) 0.212
No 40 (80%) 43 (86%) 0.531
No. of years known to be 
HIV+
≤ 4 years 18 (36%) 9 (18%) 0.007
5–10 years 22 (44%) 25 (50%) 0.231
≥ 11 years 10 (20%) 16 (32%) 0.012
CD4 cell count (cells/µl) 314 ± 160 347 ± 161 0.303
HAART duration 
(weeks)
45.7 (18.1) 62.7 (27.6) <.0001
Body composition
Body mass index (kg/
m2)
25.5 ± 2.8 24.4 ± 2.7 0.064
Waist (cm) 85.0 ± 7.0 92.3 ± 6.9 <.0001
Hip (cm) 100.3 ± 4.3 93.7 ± 6.8 <.0001
Waist-to-hip ratio 0.85 ± 0.1 0.98 ± 0.1 <.0001
Skinfold (mm)
Total skinfolds 60.4 ± 9.8 62.7 ± 12.9 0.378
Body fat mass (%) 29.1 ± 5.0 29.3 ± 4.3 0.846
Data expressed as mean ± SD, number (%) median (interquartile 
range); HIV+noBFR, HIV+ subjects with no body fat redistribution; 
HIV+BFR, HIV+ subjects with body fat redistribution.AIDS Research and Therapy 2007, 4:19 http://www.aidsrestherapy.com/content/4/1/19
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tionships domains of QoL (r2 = 0.49; p < 0.05), whereas
age was associated with independence domain of QoL (r2
= 0.69; p < 0.05). Gender was associated with psycholog-
ical domain (r2 = 0.68; p < 0.05) as well as HIV HAART-
specific wellbeing (r2 = 0.76; p < 0.05). On the other hand
CD4 cell count (r2 = 0.65; p < 0.05) and treatment dura-
tion (r2  = 0.45; p < 0.05) were associated with HIV
HAART-specific domain of wellbeing in HIV+ Rwandan
subjects with body fat redistribution.
Body changes, quality of life and gender
Figure 1 presents the relationships between body fat alter-
ations and summary scores of domains of quality of life
by gender. Certain body changes significantly influenced
HIV+ African women's mean quality of life scores than
men. In particular, body fat alterations resulting in facial
atrophy, lipohypertrophy of the neck (buffalo hump) and
atrophy of the buttocks were significantly associated with
higher mean quality of life scores. Women with BFR also
reported less satisfaction with enlargement of the abdo-
men than men. There were no considerable differences
between African men and women's perception of the
impact of body fat alterations resulting in atrophy of the
arms and enlargement of the breasts. There was a border-
line difference in satisfaction, with women reporting less
satisfaction with body changes resulting in atrophy of the
legs than men (Figure 1).
Discussion
Our findings indicate that HAART-treated HIV+ African
men and women with BFR in Rwanda experience lower
quality of life than their HIV-infected counterparts with
no body fat alterations. Specifically, HIV+ subjects with
body fat changes experienced greater psychological and
social impairment of quality of life than those without
body changes. Moreover, HIV+ patients with BFR experi-
enced more social isolation and stigma due to feeling
ashamed in public, embarrassment due to their body
image and fear of forced HIV disclosure. To our knowl-
edge, this is the first report on the relationship between
body fat redistribution and quality of life in HAART-
treated HIV+ African patients receiving WHO-recom-
mended HAART. It is also the first report on the significant
impact of HIV- and HAART-associated body changes on
quality of life in HAART-treated HIV patients in sub-Saha-
ran Africa. We believe these findings are of particular
importance due to the consequences impaired quality of
life may have on HAART adherence and treatment initia-
tives in sub-Saharan countries.
HIV-infected patients with BFR experienced social isola-
tion and lack of self esteem due to poor body image and
Table 2: Mean domain scores between subject groups, and by gender









Number 50 50 20 30 20 30
Physical 18.3 (6.4) 17.2 (3.1) 0.352 17.9 (6.5) 18.6 (6.3) 0.876 17.4 (4.1) 16.9 (2.0) 0.653
Psychological 17.1 (5.8) 11.0 (2.4) <.001 16.9 (5.6) 17.3 (5.9) 0.674 13.7 (1.9) 8.3 (2.9) <.001
Independence 17.3 (6.7) 17.6 (5.1) 0.879 17.6 (6.6) 16.9 (6.8) 0.569 17.3 (6.1) 17.9 (4.1) 0.893
Social 
relationships
17.8 (5.1) 9.0 (3.2) <.0001 17.9 (5.2) 17.6 (5.0) 0.898 11.1 (4.1) 6.9 (2.3) <.001
*HIV HAART-
specific
17.6 (5.7) 4.7 (4.2) <.0001 17.9 (5.9) 17.3 (5.4) 0.672 6.3 (3.6) 3.1 (4.8) <.001
† Overall 
aquality of life
15.7 (5.3) 15.5 (4.8) 0.889 15.6 (4.9) 15.8 (5.6) 0.935 15.8 (4.7) 15.2 (4.9) 0.598
Data expressed as median (interquartile range); ‡ Domain scores range from 4 to 20 and equals to the sum of facets divided by the number in each 
domain multiplied by 4; *Specific domain of quality of life for HAART-treated HIV patients; † other domains include overall rating of quality of life, 
satisfaction with general health, and looking forward with hope to a better future.
Quality of life and body changes by gender (n = 100; 60%  females) Figure 1
Quality of life and body changes by gender (n = 100; 60% 
females); Data expressed as median (interquartile range); on 
a summary scale of quality of life domain scores ranging from 
4–20; *p < 0.05, **p < 0.001 versus male group; +p = 0.051, 
NS1 p = 0.745; NS2 p = 0.827.
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appearance. As the diagnosis with a chronic disease can
have unfavourable impact on self esteem and interper-
sonal confidence [20], all HAART-treated HIV+ subjects
regardless of BFR, experienced low quality of life on most
domains of wellbeing. Although HIV+ patients with body
changes had more favourable immunologic outcomes of
higher CD4 counts, and were on treatment for a signifi-
cantly longer duration, they experienced more psycho-
social impairment of quality of life. Current CD4 counts
or specific HAART regimen did not predict psychological
and social wellbeing using multiple linear regression anal-
ysis, but predicted HIV HAART-specific domains of well-
being associated with stigma and marginalisation due to
HIV forced disclosure, symptoms that may impair psycho-
logical wellbeing. Other reports have shown that quality
of life in HAART-treated HIV patients deteriorate due to
the effects of body changes [21]. Psychological symptoms
due to body fat changes may influence other domains of
quality of life such physical and independence wellbeing
[20]. However, we did not observe any difference in phys-
ical and independence wellbeing between HIV+ patients
with or without body fat changes. Essentially, we cannot
assume causality of the impact of body changes on quality
of life over time due to the cross-sectional design of our
study. Secondly, time since HIV diagnosis and severity of
body fat changes did not predict any of the domains of
quality of life using multiple linear regression analysis.
However, our findings are in agreement with a report
from Western countries, that physical domain of quality
of life remains stable over time, whereas emotional stress
and psychological domain deteriorate in HAART-treated
HIV+ patients [22].
HIV+ patients with body changes felt more dishonoured
due poor body image, particularly women who experi-
enced greater marginalization as a result of changes on
their face, neck, abdomen and buttocks. Women in the
current study were more socially affected by having larger
abdomen, which in Rwanda is associated with pregnancy,
desired for by most African women but often discouraged
due to the consequences of HIV infection. Furthermore,
our findings indicate that changes in the face and reduc-
tion in size of the legs and buttocks were more associated
with impairment in body image and appearance in
women than men. However, both women and men were
equally affected by reduction in the size of the arms and
enlargement of breasts. Contrary to Western societies
where women prefer a thin body size [23], African
women, particularly those living with HIV, do not desire
a slender body image. This is due to the cultural percep-
tion in most African countries, where feminine beauty is
associated with larger body size, and the disclosure of HIV
serostatus is associated with a slim body size. However,
perception of body fat changes in the arms and breasts,
may have been partly compensated for by the nature of
dressing by most African women who often cover all their
arms and chest. Thus, the quality of life for women was
less affected by having thin arms and larger breasts.
Women may have possibly been more affected by having
both thin legs and buttocks due to less frequent dressing
covering fully the legs especially on festival occasions and
cultural perception of beauty for women with larger
'butts' and legs.
Although reports from Western countries demonstrate a
relationship between morphologic changes and use of
HAART with sexual dysfunction in HAART-treated HIV
patients [24,25], we did not observe any difference in sex-
ual satisfaction between HIV+ Rwandan patients with,
and without body fat changes. Moreover, our subjects'
perception of sexual satisfaction regardless of body fat
changes was relatively high, and further studies including
HIV seronegative subjects may ascertain these differences.
However, in the current study multiple linear regression
analysis indicated that both the duration of treatment and
CD4 count were predictors of HIV and HAART-specific
domain of quality of life. Subsequently, clinical and treat-
ment of HIV such as longer use of HAART and higher CD4
counts, which predicts development of body fat altera-
tions, appears also to be associated with quality of life in
HIV+ Rwandan subjects with body fat changes.
Studies have demonstrated evidence for adverse effects of
morphologic changes on body image and impairment of
psychological and social relationships in HIV patients
receiving HAART [26]. Our findings further demonstrate
that HIV+ African men and women with BFR experience
poor quality of life, due to forced disclosure of HIV+ diag-
nosis, stigmatization and isolation. This is consistent with
other studies in which the quality of life of HIV+ patients
with body changes if often more affected by fear of being
recognised as HIV positive, resulting in impaired psycho-
logical wellbeing than effects on overall quality of life
[27,28]. Therefore, body fat changes in HAART-treated
HIV+ patients may result in negative changes in self
esteem, interpersonal relationships, and raise questions
regarding the overall benefits of HIV treatment in the Afri-
can community. Others have shown that although
HAART was keeping HIV+ patients alive, there was often
tension between the desire for life sustaining treatment
and optimal quality of life free from failure to conceal HIV
serostatus and normal social interactions [6]. HAART- and
HIV-associated morphologic changes are as stigmatizing
as the wasting and skin lesions in the earlier years of the
disease [8], and some of the affected individuals have
described these changes as the 'Kaposi's sarcoma' of the
21st century [29]. The severity of body changes affecting
HAART-treated HIV+ Africans may compound the existing
stigma and discrimination in HIV patients [30]. Initiatives
to mitigate the effects of morphologic changes such asAIDS Research and Therapy 2007, 4:19 http://www.aidsrestherapy.com/content/4/1/19
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healthcare providers' psychological support and attention
to patients' concerns regarding the effects of body fat
changes, may potentially be beneficial, as BFR in HAART-
treated patients affect medication adherence [10,31].
As initiatives to improve wider distribution of HAART in
sub-Saharan Africa progress [3,4], the need to address the
associated problems of stigma becomes increasingly
important. Although the introduction of HAART has
improved the quality of life of HIV+ patients by reducing
HIV-related co-morbidities, the psychological and social
consequences of chronic infection with HIV and body fat
redistribution may lessen this positive impact. Therefore,
treatment initiatives need to further enforce monitoring
of the effects of HIV and HAART resulting in BFR in Africa,
as the net benefit on the overall quality of life is consid-
ered to be a balance between decreased morbidity rates
and the psycho-social symptoms of anxiety, depression
and impaired self esteem [7].
Our study is limited by being a cross-sectional evaluation,
which limits causal assumptions about the ways how
body fat changes might affect psycho-social and inde-
pendent wellbeing of HAART-treated HIV+ African
patients. As quality of life may change over time, a longi-
tudinal study could demonstrate better the relationships
between effects of the disease progression and impact of
BFR. Secondly, all subjects were on WHO-recommended
HAART, provided freely by the government and bilateral
organisations, and likely represented the general popula-
tion, whose wellbeing is often affected by an array of
financial constraints resulting in poverty which affect
quality of life.
In summary, although the benefits of antiretroviral ther-
apy cannot be underestimated, the psychological and
social impact of the associated body fat changes cannot be
ignored. Equally important to HIV treatment initiatives is
to prioritize effective monitoring methods of HIV- and
HAART-associated psychological and social consequences
to maintain high levels of adherence. Effective and appro-
priate treatment programs need to adapt a more pro-
tracted approach, which embraces evaluation of self-
perceived body changes and their determinants to
improve provided care. Patient-centred care approach in
which African patients are included in therapeutic deci-
sions and paying attention to patients' perceptions of the
effects of HAART, may contribute towards greater adher-
ence to proposed interventions and develop a more stable
quality of life continuum over time. An assessment of
quality of life is integral to efficient treatment outcomes to
evaluate long-term strategies that optimize the durability
of response to antiretroviral therapy in sub Saharan coun-
tries.
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